Jubilant Ingrevia Q1 FY27 preview: 50% PAT jump

What the Q1 FY27 preview is pointing to

Uniresearch’s preview for Jubilant Ingrevia’s Q1 FY27 results pegs a modest rise in revenue but a sharper improvement in profit after tax (PAT). The estimate is built off Q1 FY26 actuals and a trailing analysis framework, as stated in the note. For investors tracking near-term momentum, the combination of low single-digit revenue growth and strong PAT growth is the key headline. The preview also sits alongside management’s earlier commentary about sequential improvement starting Q1 FY27. That context matters because Q4 FY26 was described as the company’s highest revenue and EBITDA quarter in the last 14 quarters. The market will therefore be comparing the preview expectations with the company’s stated intent to accelerate growth from FY27.

Uniresearch estimate: revenue up 1.4%, PAT up 50%

Uniresearch projects Jubilant Ingrevia’s Q1 FY27 revenue at ₹1,052 crore, compared with ₹1,038 crore in Q1 FY26. That implies year-on-year (YoY) growth of 1.4% on the revenue line. On profitability, the estimate is for PAT of ₹112 crore versus ₹75 crore in Q1 FY26, a YoY rise of 50.0%. The preview explicitly states that the Q1 FY27 prediction is derived from trailing analysis that estimates revenue growth of +1.4% YoY and PAT growth of +50.0% YoY. The Q1 FY26 actuals are used as the base for the forecast. These are preview numbers and not company-reported Q1 FY27 results.

Q1 FY26 base numbers used for the forecast

The note cites Q1 FY26 actual revenue of ₹1,038 crore and PAT of ₹75 crore as the base period. These base numbers are critical because the preview’s YoY growth rates are calculated from them. Any investor comparing broker or research estimates should keep the base period consistent to avoid mismatched YoY calculations. The preview frames the Q1 FY27 expectations as a continuation from that base. It does not provide segment-level estimates for Q1 FY27, so the focus remains on consolidated revenue and PAT.

Key numbers snapshot (Uniresearch)

Results date: what is known and what changed

The preview states that the Q1 results date for FY27 had not yet been officially announced at the time of writing. It notes that NSE-listed companies typically disclose results dates via a board meeting notice filed on the NSE or BSE portals after the quarter ends. Separately, an update in the provided text references “Q1FY27 Quarterly Result Announced for Jubilant Ingrevia Ltd” with a timestamp of 22 Jul, 2026 (1:07 PM IST). However, no Q1 FY27 reported revenue, EBITDA, or PAT figures are provided in the same text. So, based strictly on the supplied information, the status is: the preview discussed an unannounced date, and a later line indicates the quarter’s result has been announced, without publishing the actual financial numbers.

FY26 financial base and Q4 FY26 exit run-rate

For the full year FY26, Jubilant Ingrevia reported revenue of ₹4,388 crore, EBITDA of ₹607 crore, and PAT (after exceptional items) of ₹278 crore. The FY26 EBITDA margin is stated at 13.8% versus 13.3% in FY2025. The company also reported FY26 EPS of ₹18, up 11% YoY.

Q4 FY26, which sets the exit run-rate into FY27, was reported with total revenue of ₹1,179 crore, EBITDA of ₹172 crore, and PAT (after exceptional items) of ₹86 crore. The company cited an EBITDA margin of 15% in Q4 FY26, versus 15% in Q4 FY25 and 13% in Q3 FY26. It also reported that net debt to EBITDA improved to 0.99x, and net debt reduced by 11% in 2026.

Management commentary: sequential growth from Q1 FY27, 20% EBITDA goal

In the earnings call transcript referenced in the text (filed with NSE on May 29, 2026, following a call held May 26, 2026), management stated that FY27 growth is expected to be led by Specialty Chemicals and Nutrition along with recovery in acetyls. It also said it expects sequential growth in revenue and EBITDA in coming quarters, starting from Q1 FY27 itself. Another explicit statement in the transcript is an aspiration to deliver at least 20% year-on-year growth in EBITDA for the full year FY27.

The same set of notes includes FY27 capex guidance of ₹400 to ₹500 crore. Dividend disclosures for FY26 are also included: the board recommended a final dividend of ₹2.5 per share, taking the total FY26 dividend to ₹5 per share, with a total cash outflow of ₹79.8 crore.

Stock snapshot and valuation metrics cited

The provided text includes a price point of ₹638 and a market cap of ₹11,656 crore, alongside a P/E of 42.4. It also mentions that the company shows a “moderate growth signal” based on ranking data, without detailing the underlying methodology. Since these are presented as snapshot metrics, they help frame how the market is valuing the company around the time of the preview. The same compilation of data also includes a separate price print of 740.50 with a change of -23.30 (-3.05%), but without a clear label for the date or exchange in the supplied text.

Additional historical context: Q1 FY24 performance and operational update

The provided text also references a prior period where Jubilant Ingrevia reported results for the quarter ended June 30, 2024. For that quarter, net profit declined 15.5% YoY to ₹48.7 crore, while revenue from operations fell 4.7% YoY to ₹1,024.3 crore. EBITDA declined 6.3% YoY to ₹109.5 crore, with EBITDA margin at 10.7% versus 10.9% in the corresponding period in FY24. It also states that the Bharuch manufacturing facility completed its US FDA inspection with zero 483 observations.

Why the preview matters for FY27 tracking

The preview’s main signal is the expected divergence between revenue growth (+1.4% YoY) and PAT growth (+50.0% YoY) for Q1 FY27. In parallel, management’s guidance emphasises sequential improvement from Q1 FY27 and a full-year EBITDA growth aspiration of at least 20% YoY. Investors typically read these together: near-term quarterly performance expectations and the company’s stated operating trajectory for the year. But the supplied text does not provide Q1 FY27 actual numbers, so any conclusion must remain limited to the preview estimate and previously disclosed FY26 results and guidance.

Conclusion

Uniresearch expects Jubilant Ingrevia to report Q1 FY27 revenue of ₹1,052 crore and PAT of ₹112 crore, implying 1.4% YoY revenue growth and a 50.0% YoY increase in PAT from Q1 FY26. FY26 ended with revenue of ₹4,388 crore, EBITDA of ₹607 crore, and PAT of ₹278 crore, while management has communicated sequential growth starting Q1 FY27 and an aspiration of at least 20% YoY EBITDA growth for FY27. The preview noted the results date was not officially announced, although a later update in the provided text indicates Q1 FY27 results have been announced, with details expected through filings and commentary.